Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Background/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2019-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2018-0029.pdf |
id |
doaj-0c37bf0820804bbabe6b3931107fbda2 |
---|---|
record_format |
Article |
spelling |
doaj-0c37bf0820804bbabe6b3931107fbda22020-11-25T02:45:51ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2019-03-01251425110.3350/cmh.2018.00291435Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patientsChristian Mölleken0Maike Ahrens1Anders Schlosser2Julia Dietz3Martin Eisenacher4Helmut E. Meyer5Wolff Schmiegel6Uffe Holmskov7Christoph Sarrazin8Grith Lykke Sorensen9Barbara Sitek10Thilo Bracht11 Department of Gastroenterology and Hepatology, University Hospital Bergmannsheil, Bochum, Germany Medizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark Medical Clinic 1, J.W. Goethe University Hospital, Frankfurt, Germany Medizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany Medizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany Department of Gastroenterology and Hepatology, University Hospital Bergmannsheil, Bochum, Germany Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark Medical Clinic 1, J.W. Goethe University Hospital, Frankfurt, Germany Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark Medizinisches Proteom-Center, Ruhr University Bochum, Bochum, Germany Medizinisches Proteom-Center, Ruhr University Bochum, Bochum, GermanyBackground/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon p<0.001 for both). Conclusions Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.http://e-cmh.org/upload/pdf/cmh-2018-0029.pdfHepatitis C, ChronicBiomarkersLiver cirrhosisAntiviral agentsExtracellular matrix proteins |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christian Mölleken Maike Ahrens Anders Schlosser Julia Dietz Martin Eisenacher Helmut E. Meyer Wolff Schmiegel Uffe Holmskov Christoph Sarrazin Grith Lykke Sorensen Barbara Sitek Thilo Bracht |
spellingShingle |
Christian Mölleken Maike Ahrens Anders Schlosser Julia Dietz Martin Eisenacher Helmut E. Meyer Wolff Schmiegel Uffe Holmskov Christoph Sarrazin Grith Lykke Sorensen Barbara Sitek Thilo Bracht Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients Clinical and Molecular Hepatology Hepatitis C, Chronic Biomarkers Liver cirrhosis Antiviral agents Extracellular matrix proteins |
author_facet |
Christian Mölleken Maike Ahrens Anders Schlosser Julia Dietz Martin Eisenacher Helmut E. Meyer Wolff Schmiegel Uffe Holmskov Christoph Sarrazin Grith Lykke Sorensen Barbara Sitek Thilo Bracht |
author_sort |
Christian Mölleken |
title |
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
title_short |
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
title_full |
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
title_fullStr |
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
title_full_unstemmed |
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
title_sort |
direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis c patients |
publisher |
Korean Association for the Study of the Liver |
series |
Clinical and Molecular Hepatology |
issn |
2287-2728 2287-285X |
publishDate |
2019-03-01 |
description |
Background/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon p<0.001 for both). Conclusions Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus. |
topic |
Hepatitis C, Chronic Biomarkers Liver cirrhosis Antiviral agents Extracellular matrix proteins |
url |
http://e-cmh.org/upload/pdf/cmh-2018-0029.pdf |
work_keys_str_mv |
AT christianmolleken directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT maikeahrens directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT andersschlosser directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT juliadietz directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT martineisenacher directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT helmutemeyer directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT wolffschmiegel directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT uffeholmskov directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT christophsarrazin directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT grithlykkesorensen directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT barbarasitek directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients AT thilobracht directactingantiviralsbasedtherapydecreaseshepaticfibrosisserumbiomarkermicrofibrillarassociatedprotein4inhepatitiscpatients |
_version_ |
1724759650081964032 |